Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.
J Virol
; 87(24): 13892-9, 2013 Dec.
Article
em En
| MEDLINE
| ID: mdl-24067970
ABSTRACT
We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dipeptidil Peptidase 4
/
Coronaviridae
/
Infecções por Coronaviridae
/
Anticorpos Monoclonais
/
Anticorpos Antivirais
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article